ClinVar Miner

Submissions for variant NM_022489.4(INF2):c.2065C>T (p.Arg689Trp)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV002422033 SCV002724866 uncertain significance Inborn genetic diseases 2021-04-02 criteria provided, single submitter clinical testing The p.R689W variant (also known as c.2065C>T), located in coding exon 11 of the INF2 gene, results from a C to T substitution at nucleotide position 2065. The arginine at codon 689 is replaced by tryptophan, an amino acid with dissimilar properties. This variant was detected in an individual with focal segmental glomerulosclerosis (FSGS), who was compound heterozygous for INF p.R689W and a splice site variant in COL4A3 (Bullich G et al. Eur J Hum Genet, 2015 Sep;23:1192-9). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Labcorp Genetics (formerly Invitae), Labcorp RCV003775085 SCV004586197 likely benign Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E 2024-09-30 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.